- Home
- IBTA vs DSGN Comparison
IBTA vs DSGN Comparison
Compare IBTA & DSGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | IBTA | DSGN |
|---|---|---|
| Founded | 2011 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 604.2M | 579.9M |
| IPO Year | 2024 | 2021 |
Fundamental Metrics
Financial Performance| Metric | IBTA | DSGN |
|---|---|---|
| Price | $22.09 | $10.12 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 8 | 3 |
| Target Price | ★ $30.57 | $15.00 |
| AVG Volume (30 Days) | 252.2K | ★ 254.3K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 80.28 | 26.05 |
| EPS | ★ 0.15 | N/A |
| Revenue | ★ $367,254,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $143.87 | ★ N/A |
| Revenue Growth | ★ 14.75 | N/A |
| 52 Week Low | $19.10 | $2.62 |
| 52 Week High | $68.40 | $10.97 |
Technical Indicators
Market Signals| Indicator | IBTA | DSGN |
|---|---|---|
| Relative Strength Index (RSI) | 52.23 | 50.81 |
| Support Level | $20.06 | $9.70 |
| Resistance Level | $21.83 | $10.40 |
| Average True Range (ATR) | 1.22 | 0.51 |
| MACD | 0.16 | -0.05 |
| Stochastic Oscillator | 91.42 | 43.73 |
Price Performance
Historical ComparisonAbout IBTA Ibotta Inc.
Ibotta Inc is a performance marketing platform. It allows CPG brands to deliver digital promotions to consumers through a single, convenient network called the Ibotta Performance Network (IPN).
About DSGN Design Therapeutics Inc.
Design Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the research and development of GeneTACTM molecules, which are a novel class of small-molecule gene-targeted chimera therapeutic candidates designed to be disease-modifying by addressing the underlying cause of diseases caused by inherited nucleotide repeat expansion mutations. The Company's product candidate is in Friedreich ataxia (FA), its second product candidate is in Fuchs endothelial corneal dystrophy (FECD), and it is also advancing its GeneTACTM program to address other serious nucleotide repeat-driven monogenic diseases.